18 October 2021 - NICE has recommended Boehringer Ingelheim’s Ofev (nintedanib) for the treatment of adult patients with chronic fibrosing interstitial lung diseases with a progressive phenotype.

The recommendation is supported by data from the Phase 3 INBUILD trial, which found Ofev met the primary endpoint of significantly slowing disease progression – defined as an absolute decline in forced vital capacity over 52 weeks in patients with chronic fibrosing interstitial lung diseases with a progressive phenotype versus placebo.

Read Pharma Times article